Slide 1: Welcome to LENZ's Key Opinion Leader Event
WELCOME TO LENZ’s KEY OPINION LEADER EVENT Featuring Capstone Phase 3 Data and KOL / Principal Investigator Perspectives TUESDAY, JUNE 18TH – 8:00 – 9:30AM ET 1 NASDAQ: LENZ
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are
Slide 3: Today's agenda and presenters
Today’s agenda and presenters 1 2 3 4 5 6 Welcome Capstone data KOL view Panel discussion Q&A Wrap up LENZ Management: Eye Care Professional KOLs and CLARITY Study Investigators: Eef Schimmelpennink Marc Odrich, MD Jason Bacharach, MD Marc Bloomenstein, OD Milton Hom, OD President and CEO Chief Medi
Slide 4: Presbyopia largest eyecare market
Presbyopia largest eyecare market 128M US presbyopes 78M US patients Glaucoma 3M Diabetic Retinopathy 8M Macular Degeneration 11M Childhood Myopia 20M Dry Eye 36M Presbyopia Everything Else 4
Slide 5: Looking for an 'All Eyes – All Day' eye drop
Looking for an ‘All Eyes – All Day’ eye drop Presbyopia CLARITY 1&2 Market Research LNZ100 Participants 60% 75% Would seriously Would continue consider to use 80% 81% 4 – 7 days/wk 4 – 7 days/wk1 Market research based on survey of over 1,358 Presbyopes. Participant feedback based on pooled responses
Slide 6: LNZ100 delivers on this opportunity with ideal profile
LNZ100 delivers on this opportunity with ideal profile Established as undisputed best-in-class Ages 45 – 75, Refractive range Inclusive of post-LASIK Baseline near visual Mean 55 years -4D SE to +1D SE presbyopes and pseudophakes acuity 20/50 or worse Participants represent majority of 128M US presb
Slide 7: LNZ100 has Blockbuster Potential
LNZ100 has Blockbuster Potential $3B US market at conservative 6% adoption or ~8M users and 3 days/wk Large TAM and ex-US markets provide additional growth opportunities 7 Numbers based on LENZ internal analysis and estimates and at Vuity pricing of $79 / month
Slide 8: Capstone CLARITY data confirms LNZ100 ideal profile
Capstone CLARITY data confirms LNZ100 ideal profile 99.6% of participants achieved sweet spot of 1 <2mm pupil size Largest human study confirmed <2mm pupil without ciliary muscle stimulation improves both near and distance vision 3 lines of NV improvement was only the 2 beginning 84% achieved at lea
Slide 9: Capstone Data
Capstone Data 1 2 3 4 5 6 Welcome Capstone data KOL view Panel discussion Q&A Wrap up Additional data analysis of the CLARITY Trials: Marc Odrich, MD Ophthalmologist, LENZ Chief Medical Officer Associate Professor of Cornea /Refractive Surgery University of Virginia 9
Slide 10: Pupil <2mm proven sweet spot for near vision improvement
Pupil <2mm proven sweet spot for near vision improvement CLARITY confirmed pupil biomarker with largest in-human miotic near vision study Probability of Achieving ≥3-Line Near Vision Improvement by Pupil Size 78% 99.6% (233/234) participants on LNZ100 achieved <2mm pupil 2mm 68% only presbyopia eyed
Slide 11: Providing best-in-class near vision with ideal product profile
Providing best-in-class near vision with ideal product profile % of Participants Achieving ≥2 and ≥3-Line Near Vision Improvement (no loss of 1 line or more BCDVA) ≥2 line ≥3 line Once daily, rapid onset, long 95% duration for vast majority of 91% 91% 87% presbyopes makes LNZ100 the 78% 78% 78% idea
Slide 12: 3-line near vision improvement was only the beginning
3-line near vision improvement was only the beginning % Participants Achieving Near Vision Improvement by Line LNZ100 (n=234) Vehicle (n=76) 84% 84% of participants achieved a 4-line gain at some point during the efficacy studies 52% 52% of participants achieved a 5-line gain 24% 88% of participants
Slide 13: Lines of NV improvement increases as presbyopia advances
Lines of NV improvement increases as presbyopia advances % Participants Achieving NV Improvement by Line During Study Advanced Presbyopia >20/80 (n=76) Moderate Presbyopia 20/40-20/80 (n=158) 92% More lines of improvement for 80% those that need more 68% As presbyopia advances LNZ100 provides greate
Slide 14: Ideal pupil size for distance vision is also below 2mm
Ideal pupil size for distance vision is also below 2mm Mean distance vision improvement peaked at 1.5 – 1.75mm Mean Change to Baseline Distance Vision by Pupil Size Largest in-human study with over 14,500 pupil measurements -0.06 2mm -0.05 Mean distance vision -0.04 -0.04 improvement peaked at LogMA
Slide 15: Statistically significant improvement in distance vision
Statistically significant improvement in distance vision Even while distance corrected to 20/25 or better when tested, 41% of participants achieved 1-line or more of distance vision improvement % of Participants Achieving ≥1-Line Distance Vision Improvement LNZ100 (n=234) Vehicle (n=76) 41% 38% 39%
Slide 16: LNZ100 well tolerated with high rate of study completion
LNZ100 well tolerated with high rate of study completion Headaches were few and transient, mostly mild and appear tachyphylactic CLARITY 1, 2 and 3 Participant Disposition Less than 4% discontinue-rate due to treatment related AEs (trAE) LNZ100 Control (CLARITY 1,2,3) (CLARITY 1,2,3) Few participant
Slide 17: KOL View
KOL View 1 2 3 4 5 6 Welcome Capstone data KOL view Panel discussion Q&A Wrap up Eye Care Professional KOLs and CLARITY Study Investigator: Jason Bacharach, MD Ophthalmologist, Clinical Investigator in CLARITY Trial 17
Slide 18: Panel Discussion
Panel Discussion 1 2 3 4 5 6 Welcome Capstone data KOL view Panel discussion Q&A Wrap up Eye Care Professional KOLs and CLARITY Study Investigators: Marc Bloomenstein, OD Optometrist Milton Hom, OD Optometrist 18
Slide 19: Q&A
Q&A 1 2 3 4 5 6 Welcome Capstone data KOL view Panel discussion Q&A Wrap up Jason Bacharach, MD Marc Bloomenstein, OD Milton Hom, OD 19 Ophthalmologist Optometrist Optometrist
Slide 20: Thank You
THANK YOU 20